Schott brings significant experience advising pharmaceutical manufacturers in connection with price reporting and other compliance obligations under the Medicaid, Medicare, and 340B drug pricing programs, which includes supporting the entire product lifecycle, from pre-launch considerations, to commercialization and contracting strategies, to decisions around authorized generics and line extensions. He also regularly advises clients in connection with pricing methodology audits and interactions with federal regulators. Schott draws on his regulatory expertise and understanding of the industry to support a range of corporate transactions in the pharmaceutical space, including acquisitions and divestitures as well as licensing and co-promotion arrangements.

“Chris will be an excellent addition to our Washington, D.C. office” said Daniel Lennon, Office Managing Partner of the firm’s Washington, D.C. office. “Here in the nation’s capital, we combine classic litigation and regulatory practices with our premier transactional practices. With his extensive regulatory background, industry knowledge, and transactional experience, Chris will be a perfect complement to the team and an asset to clients around the world as they seek to do business in the US.”

“Latham is well known for its healthcare and life sciences regulatory work and I am thrilled to be joining these best-in-class practitioners” said Schott. “The firm’s integrated global platform and dynamic team-oriented approach provide a powerful basis for supporting my clients, not only in the evolving drug pricing environment, but more broadly as well. I look forward to contributing to the continued success of the Healthcare & Life Sciences Practice.”

Schott earned his JD with high honors from The George Washington University Law School and his BA from the University of Maryland.